The global in-vitro inflammatory bowel disease diagnostic market size was surpassed US$ 1.69 Billion in 2021 and is expected to reach around USD 2.41 billion by 2030 with a CAGR of 4% from 2022 to 2030.
The global in-vitro inflammatory bowel disease diagnostic market size was surpassed US$ 1.69 Billion in 2021 and is expected to reach around USD 2.41 billion by 2030 with a CAGR of 4% from 2022 to 2030.
Inflammatory bowel disease (IBD) is a terms used to describe disorders that involve chronic inflammation of the digestive tract. Inflammatory bowel disease (IBD) includes ulcerative colitis and Crohn’s disease. Assays/biomarkers and analyzers are used to diagnose in-vitro inflammatory bowel disease. The rise in prevalence of inflammatory bowel disease and an increase in the demand for less-invasive, resource-benefit boost the global in-vitro inflammatory bowel disease diagnostic market. North America dominated the global in-vitro inflammatory bowel disease diagnostic market in 2019. The trend is anticipated to continue during the forecast period. High prevalence of diseases and well-established healthcare infrastructure enable proper diagnosis of IBD are responsible for high market share of the region.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/35812
Asia Pacific is expected to be a highly lucrative market for in-vitro inflammatory bowel disease diagnostic during the forecast period. Majority of countries in Asia Pacific are economically developing and numerous players are making significant investment in the region. These factors boost the market in Asia Pacific. The rise in technological advancements in countries in terms of healthcare and medical research is anticipated to fuel the market in the region.
High Prevalence of Inflammatory Bowel Disease (IBD) and Newer Biomarkers Offer Significant Opportunities
According to IBD Support Australia Incorporated, in 2015, around 61,000 people in Australia are affected by inflammatory bowel disease of which, around 28,000 people are affected by Crohn’s disease and 33,000 are affected by ulcerative colitis. Furthermore, according to New Zealand Ministry of Health more than 15,000 people are affected by IBD in New Zealand. New Zealand and Australia have a high prevalence of IBD in the world. Thus, rising cases of inflammatory bowel diseases boost the global market.
Major innovations in diagnostic technologies include the development of more sophisticated endoscopic and noninvasive techniques to improve the identification of complications, in particular, in malignant diseases associated with IBD. The future would see further progress in the identification of genetic susceptibility factors and of protein biomarkers and their use to describe the molecular epidemiology of IBD. It is expected that future diagnostics would include molecular parameters to detect early disease or guide therapies by predicting the individual course of disease.
In November 2016, Inova Diagnostics, announced the U.S Food and Drug Administration (FDA) clearance of QUANTA Lite Calprotectin Extended Range, an assay which aids in the diagnosis of Inflammatory Bowel Disease (IBD) and can help differentiate IBD from Irritable Bowel Syndrome (IBS).
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 1.69 billion |
| Revenue Forecast by 2030 | USD 2.41 billion |
| Growth rate from 2022 to 2030 | CAGR of 4% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Type, Route of Administration, Application, Region |
| Companies Covered | DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Abbott, Quidel Corporation, American Laboratory Products Company (ALPCO), Certest Biotec SL., and Biosystems S.A |
Assays/Biomarker to Dominate Market
In terms of product, the global in-vitro inflammatory bowel disease diagnostic market has been divided into assays/biomarker and analyzers. The assays/biomarker segment has been further subdivided into calprotectin, lactoferrin, bile acids, H. pylori SA, pancreatic elastase, and others. The assays/biomarker segment dominated the global in-vitro inflammatory bowel disease diagnostic market in 2019. The trend is likely to continue during the forecast period, owing to an increase in cases of nerve pain and launch of new products.
In June 2019, Bühlmann Laboratories received 510(k) clearance from the U.S. Food and Drug Administration for its fCal Turbo calprotectin test, which is an immuno turbidimetric fecal calprotectin assay. fCAL turbo assay represents a high-throughput option to the company’s recently FDA-cleared fCal ELISA assay.
Hospitals to be Promising End User
Based on end user, the global in-vitro inflammatory bowel disease diagnostic market has been classified into diagnostic laboratories, hospitals, and research institutes. The hospitals segment is expected to expand at a notable CAGR during the forecast period. The expansion of the segment can be attributed to a rise in the rate of hospitalization for inflammatory bowel diseases and a wide range of services offered by hospitals at a single site.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/35812
Growing Adoption of Biomarkers and Analyzers to Fuel Market Growth
The growing prevalence of Crohn’s disease (CD) and ulcerative colitis (UC) in several regions of the world has played a key role in boosting the adoption of biomarkers and analyzers, which, in turn, is expected to propel the growth of the global in-vitro inflammatory bowel disease diagnostics market during the assessment period. The demand for predictive biomarkers has witnessed consistent growth as the need to efficiently assess the mucosal disease activity in inflammatory bowel diseases has become imperative. Serum-based biomarkers have gained considerable traction across the global in-vitro inflammatory bowel disease diagnostics market in recent times and as per current observations, this trend is likely to provide a considerable push to the growth of the market for in-vitro inflammatory bowel disease diagnostics.
Demand to Remain Sluggish amid COVID-19 Pandemic
The healthcare sector has arguable remained one of the busiest core sectors during the ongoing COVID-19 pandemic, as researchers, scientists, and other stakeholders in the healthcare sector are increasingly focusing on discovering vaccines to contain the novel coronavirus. The progress in in-vitro inflammatory bowel disease diagnostics has remained relative slower. Although research and development activities are expected to continue during the ongoing pandemic, the adoption of in-vitro inflammatory bowel disease diagnostics is expected to remain sluggish, particularly in 2020 due to the fear among patients pertaining to contracting the novel coronavirus in hospitals.
North America to Dominate Global Market
The global in-vitro inflammatory bowel disease diagnostic market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2019, followed by Europe. North America accounted for a major share of the global in-vitro inflammatory bowel disease diagnostic market in 2019, owing to rise in the rate of adoption of new technology for detection of diseases and an increase in the number of various disorders. The in-vitro inflammatory bowel disease diagnostic market in Asia Pacific is anticipated to expand at a higher CAGR from 2020 to 2030. The expansion of the in-vitro inflammatory bowel disease diagnostic market in the region can be attributed to a rise in prevalence of disorders and an increase in awareness about diagnosis in the region.
Competition Landscape
DiaSorin S.p.A, BÜHLMANN Laboratories AG, and F. Hoffmann-La Roche AG are leading players operating in the global in-vitro inflammatory bowel disease diagnostic market and hold majority market share. The global in-vitro inflammatory bowel disease diagnostic market is fragmented in terms of number of players. Key players in the global market include DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Abbott, Quidel Corporation, American Laboratory Products Company (ALPCO), Certest Biotec SL., and Biosystems S.A. New product development through robust R&D activities and mergers & acquisitions are key strategies adopted by these players to operate their business in the global in-vitro inflammatory bowel disease diagnostic market.
Market Segmentation
By Product
- Assays/Biomarker
- Calprotectin
- Lactoferrin
- Bile Acids
- H. pylori SA
- Pancreatic Elastase
- Others
- Analyzers
By End User
- Diagnostic Laboratories
- Hospitals
- Research Institutes
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/35812
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/